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STATIN THERAPY SIGNIFICANTLYreduces cardiovascular eventsamong individuals with andwithout a history of diabetes
mellitus compared with placebo.1,2
Intensive-dose statin therapy has
also been shown to further reduce car-
diovascular events compared with mod-
erate-dose statin therapy.1,3 A recent
meta-analysis of 13 randomized pla-
cebo and standard care controlled trials
involving 91 140 individuals reported
that among patients treated with stat-
ins, the risk of developing diabetes was
9% higher (95% confidence interval
[CI], 2%-17%) over a 4-year period
compared with patients randomized to
placebo or standard care.4 Recently,
findings of 3 large end-point trials com-
paring intensive- to moderate-dose
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Context A recent meta-analysis demonstrated that statin therapy is associated with
excess risk of developing diabetes mellitus.
Objective To investigate whether intensive-dose statin therapy is associated with
increased risk of new-onset diabetes compared with moderate-dose statin therapy.
Data Sources We identified relevant trials in a literature search of MEDLINE, EMBASE,
and the Cochrane Central Register of Controlled Trials (January 1, 1996, through March
31, 2011). Unpublished data were obtained from investigators.
Study Selection We included randomized controlled end-point trials that com-
pared intensive-dose statin therapy with moderate-dose statin therapy and included
more than 1000 participants who were followed up for more than 1 year.
Data Extraction Tabular data provided for each trial described baseline characteris-
tics and numbers of participants developing diabetes and experiencing major cardiovas-
cular events (cardiovascular death, nonfatal myocardial infarction or stroke, coronary
revascularization). We calculated trial-specific odds ratios (ORs) for new-onset diabetes
and major cardiovascular events and combined these using random-effects model meta-
analysis. Between-study heterogeneity was assessed using the I2 statistic.
Results In 5 statin trials with 32 752 participants without diabetes at baseline, 2749 de-
veloped diabetes (1449 assigned intensive-dose therapy, 1300 assigned moderate-dose
therapy, representing 2.0 additional cases in the intensive-dose group per 1000 patient-
years)and6684experiencedcardiovascularevents(3134and3550,respectively,representing
6.5 fewer cases in the intensive-dosegroupper1000patient-years)over aweightedmean
(SD) follow-up of 4.9 (1.9) years. Odds ratios were 1.12 (95% confidence interval [CI],
1.04-1.22; I2=0%)fornew-onsetdiabetesand0.84(95%CI,0.75-0.94; I2=74%)forcardio-
vascular events forparticipants receiving intensive therapycomparedwithmoderate-dose
therapy. As compared with moderate-dose statin therapy, the number needed to harm
peryear for intensive-dosestatin therapywas498fornew-onsetdiabeteswhile thenumber
neededto treatperyear for intensive-dosestatin therapywas155forcardiovascularevents.
Conclusion In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy
was associated with an increased risk of new-onset diabetes compared with moderate-
dose statin therapy.
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statin therapy have suggested an ex-
cess risk of incident diabetes among
those treated with intensive statin regi-
mens.5,6 However, 2 of these trials used
nonstandard diagnostic criteria pre-
viously used to define incident diabe-
tes.7 Additionally, published data
from a fourth large clinical trial sug-
gested the possibility of a deteriora-
tion in glucose control in patients
receiving intensive statin therapy,8
and a recent report of 220 patients
with hypercholesterolemia treated
with placebo or different doses of
atorvastatin and followed up for only
2 months found that those receiving
the highest dose developed greater
insulin resistance, higher insulin lev-
els, and higher hemoglobin A1c levels
compared with those receiving the
lowest dose or placebo,9 suggesting a
potential dose effect. Although no
significant relationship was observed
between the extent of decreasing
low-density lipoprotein (LDL) cho-
lesterol values and new-onset diabe-
tes in the meta-analysis of placebo
and standard care controlled trials,4
most of those trials used modest-
intensity statins and trial populations
also differed greatly, which may have
obscured any meaningful association.
Confidence in the observed associa-
tion between statin therapy and the
development of diabetes would be
enhanced by providing further large-
scale evidence of a dose-dependent
association.4 Given the cardiovascular
benefits of statins and the likely
increasing use of intensive statin regi-
mens, it is important to quantify any
potential long-term risks to enable
physicians and patients to make
informed choices. Furthermore, it
would be of value to investigate
whether any specific group of patients
is at higher risk of diabetes when
receiving intensive statin therapy than
others. We therefore examined the
associations of intensive-dose statin
therapy vs moderate-dose therapy
with the development of diabetes and
the occurrence of major cardiovascu-
lar events, respectively, by conducting
a collaborative meta-analysis of pub-
lished and unpublished data from rel-
evant clinical trials.
METHODS
We gathered data from large random-
ized end-point statin trials primarily de-
signed to assess the effect of intensive-
dose statin treatment compared with
moderate-dose therapy on cardiovas-
cular outcomes. Inclusion criteria in-
cluded trials of 1000 or more partici-
pants exposed to statin therapy with a
minimum mean follow-up of 1 year.
Length of follow-up in both treatment
groups was required to be identical to
avoid bias in ascertainment of new-
onset diabetes. We searched MEDLINE,
EMBASE, and the Cochrane Central
Register of Controlled Trials with the
terms statin andHMGCoA reductase in-
hibitor and names of individual statins
as title words and keywords and com-
bined these with a search for the key-
words intensive or aggressive to iden-
tify trials performed in adult patients
(initial search date, January 8, 2010; up-
dated April 4, 2011) and published in
English from January 1, 1996, until
March 31, 2011 (FIGURE 1). Abstracts
and manuscripts were reviewed inde-
pendently by 2 readers (D.P. and P.W.).
A third reviewer (N.S.) settled dis-
crepancies. After the full articles were
reviewed, 5 trials were excluded,10-14
and 5 trials were included in the
analysis: the Treating to New Targets
(TNT) tr ia l , 1 5 the Incremental
Decrease in End Points Through
Aggressive Lipid Lowering (IDEAL)
trial,16 the Aggrastat to Zocor (A to Z)
trial,17 the Pravastatin or Atorvastatin
Evaluation and Infection Therapy–
Thrombolysis in Myocardial Infarc-
tion (PROVE IT–TIMI 22) trial,18 and
the Study of the Effectiveness of Addi-
tional Reductions in Cholesterol and
Homocysteine (SEARCH).5
Data Sources
Investigators from all 5 trials provided
data for incident diabetes and major car-
diovascular events according to a stan-
dard data query sheet (eFigure 1, avail-
able at http://www.jama.com). To
ascertain whether any specific patient
subgroups were at greater risk of de-
Figure 1. Flow Diagram of the Literature Search
20 Full-text articles read (representing
10 trials)
5 Trials identified and data requested
from investigators
10 Articles from other sources
475 Excluded (duplicates)
753 Abstracts reviewed
5 Trials included in analysis
733 Excluded (most for >1 reason)
211 Surrogate CVD markers, follow-up
<1 y, or <1000 patients
71 Placebo-controlled trials
310 Post hoc analyses or not RCTs
26 Patients with diabetes
115 Other agents or treatments
1218 Articles from MEDLINE, EMBASE,
and Cochrane Central Register of
Controlled Trials 
5 Trials excluded (6 articles) 
3 Surrogate marker for primary
outcome and <1000 participants
1 Surrogate marker for primary
outcome
1 Different follow-up in both
treatment groups
CVD indicates cardiovascular disease; RCTs, randomized controlled trials.
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veloping diabetes while receiving in-
tensive statin therapy, we collected data
on the key end points among those with
data for body mass index (BMI), high-
density lipoprotein (HDL) choles-
terol, triglycerides, age, and fasting
plasma glucose (FPG) (where avail-
able) above and below the trial medi-
ans, as these factors are associated with
diabetes risk. A PRISMA checklist was
provided at the time of manuscript sub-
mission.19
Quality Assessment
Twoauthors (D.P.andP.W.)usedanes-
tablished tool20 to independently evalu-
ate the quality of each trial. Nine char-
acteristicswereassessed:randomization;
concealmentoftreatmentallocation;simi-
larityofgroupsatbaseline; eligibilitycri-
teria;whetheroutcomeassessors,partici-
pants, and care providers, respectively,
were blinded to treatment allocation;
availability of point estimates; and in-
tention-to-treat analysis, thereby allow-
ing each trial to be awarded a Delphi
scoreof0to9.Disagreementwasresolved
through consensus and discussion.
End Points
A patient was considered to have de-
veloped diabetes if (1) there was an ad-
verse event report of newly diagnosed
diabetes during the trial, (2) he or she
commenced glucose-lowering medica-
tion during the trial, or (3) he or she
had 2 FPG values of 126 mg/dL or
greater during the trial. (To convert glu-
cose to mmol/L, multiply by 0.0555.)
For the 2 trials with data published
using nonstandard diabetes criteria (as
in the third criterion but also requir-
ing a36-mg/dL increase in FPG from
baseline),6 we performed a reanalysis
of the data using the standard diagnos-
tic criteria but also included a sensitiv-
ity analysis using the nonstandard cri-
teria previously used in the West of
Scotland Coronary Prevention Study.7
We also collected data on a composite
cardiovascular end point consisting of
cardiovascular death, nonfatal myocar-
dial infarction, nonfatal stroke, coro-
nary artery bypass surgery, and percu-
taneous coronary intervention as well
as data for specific cardiovascular events
and all-cause mortality. For trials that
recruited patients shortly after an acute
coronary syndrome (ACS), we used the
prespecified trial definitions that in-
cluded only those revascularization pro-
cedures not linked to the prerandom-
ization index event. These consisted of
procedures performed more than 30
days after randomization in the PROVE
IT–TIMI 22 study and only ischemia-
driven procedures in the A to Z study.
Statistical Analysis
To identify potential associations of in-
tensive-dose vs moderate-dose statin
therapy with incident diabetes and car-
diovascular events, we calculated odds
ratios (ORs) and 95% CIs from the
available data for the number of pa-
tients who did not have diabetes at base-
line and those who developed diabe-
tes and cardiovascular events during
follow-up. Study-specific ORs were
pooled using a random-effects model
meta-analysis to account for between-
study heterogeneity that may have been
introduced by the differing methods for
diagnosing diabetes available in the
trials and different trial populations. Sta-
tistical heterogeneity across studies was
quantified using the 2 (or Cochran Q
statistic) and I2 statistics, with P.10
considered statistically nonsignifi-
cant. The I2 statistic is derived from the
Q statistic ([Q−df/Q]100) and pro-
vides a measure of the proportion of
the overall variation attributable to
between-study heterogeneity.21 Al-
though we used both published and un-
published information in our meta-
analysis, we nevertheless assessed the
potential for publication bias through
formal tests, namely the funnel plot and
Egger test. To evaluate the effect of stat-
ins across clinically relevant sub-
groups, we calculated stratum-
specific ORs for incident diabetes and
major cardiovascular events and com-
bined them using random-effects meta-
analysis. In exploratory analyses, we
compared results in patients with re-
cent ACS with those with stable coro-
nary heart disease and also compared
results for trials in which simvastatin
80 mg and atorvastatin 80 mg were the
respective intensive regimens. All P val-
ues were 2-sided and P .05 was con-
sidered statistically significant. Analy-
ses were conducted using Stata version
10.1 (StataCorp, College Station,
Texas).
RESULTS
Five randomized clinical trials pro-
vided data on 32 752 nondiabetic par-
ticipants over a weighted mean (SD) fol-
low-up of 4.9 (1.9) years. During
follow-up, 2749 participants (8.4%) de-
veloped diabetes (1449 of whom were
assigned intensive-dose therapy, 1300
assigned moderate-dose therapy), and
6684 (20.4%) experienced a major car-
diovascular event (3134 assigned in-
tensive-dose therapy, 3550 assigned
moderate-dose therapy) (TABLE 1,
TABLE 2, and FIGURE 2). Of the 2749
diagnoses of diabetes, 2059 (75%) were
identified by nonbiochemical meth-
ods (ie, commencement of glucose-
lowering medication or adverse event
reporting), 219 (8%) by elevated FPG
values in the trial, and 471 (17%) by
more than 1 method. Trials were of high
quality with a median Delphi score of
9 (range, 6-9).
New-Onset Diabetes
In the combined data set, there were
149 more cases of incident diabetes in
participants assigned to intensive statin
treatment than in those receiving mod-
erate therapy (OR, 1.12; 95% CI, 1.04-
1.22) (Figure 2). In absolute terms,
there were 2.0 additional cases of dia-
betes per 1000 patient-years among
those receiving intensive-dose therapy
(mean [SD] 18.9 [5.2] cases per 1000
patient-years with high-dose statin
treatment vs 16.9 [5.5] cases per 1000
patient-years with moderate-dose
therapy), corresponding to a number
needed to harm of 498 per year. There
was no significant heterogeneity be-
tween trials for new-onset diabetes (2
for heterogeneity=2.59; P=.60; I2=0%
[95% CI, 0%-79%]). Likewise, there
was no evidence of publication bias
(P=.54) (eFigure 2).
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Cardiovascular Benefit
In the combined data set, there were
416 fewer patients with cardiovascu-
lar events who received intensive-
dose therapy (OR, 0.84; 95% CI, 0.75-
0.94) (Figure 2). In absolute terms,
there were 6.5 fewer first major cardio-
vascular events per 1000 patient-years
among those receiving intensive statin
therapy (mean [SD] 44.5 [20.4] cases
per 1000 patient-years with high-dose
treatment and 51.0 [23.6] cases per
1000 patient-years with moderate-
dose therapy), corresponding to a num-
ber needed to treat of 155 to prevent 1
cardiovascular event per year. There
was significant heterogeneity between
trials for major cardiovascular events
(2 for heterogeneity=15.04; P=.004;
I2=74% [95% CI, 36%-90%]). How-
ever, there was no evidence of publi-
cation bias (P=.70) (eFigure 2). Odds
ratios for specific components of the
composite cardiovascular end point are
provided in TABLE 3, showing similar
associations between intensive statin
therapy and each cardiovascular end
point component. Intensive-dose
therapy was not associated with lower
all-cause mortality compared with mod-
erate-dose statin therapy (OR, 0.93;
95% CI, 0.81-1.05; 1318 cases/16 408
patients receiving intensive therapy vs
1360 cases/16 342 patients receiving
moderate doses). Intensive statin
therapy was not associated with lower
Table 1. Descriptions of the 5 Included Trials Comparing Intensive-Dose to Moderate-Dose Statin Therapy
Source
No Diabetes/
All Patients,
No. (%)a
Trial
Population
Intensive/
Moderate Regimen
Received
Intensive/
Received
Moderate, No. Follow-up, yb
Methods of
Diagnosing Diabetes
Cannon et al
(PROVE IT–TIMI 22),18
2004
3395/4162 (82) Recent ACS Atorvastatin 80 mg/
pravastatin 40 mg
1707/1688 2.0 (0.6) (1) AE report, (2) DM
medication, (3)
FPG126 mg/dL
twice
de Lemos et al
(A to Z),17 2004
3504/4497 (78) Recent ACS Simvastatin 40 mg,
simvastatin 80 mg/
placebo,
simvastatin 20 mg
1768/1736 2.0 (1.5-2.0) (1) AE report, (2) DM
medication
LaRosa et al
(TNT),15 2005c
7595/10 001 (76) Stable CHD Atorvastatin 80 mg/
atorvastatin 10 mg
3798/3797 5.0 (0.5) (1) AE report, (2) DM
medication, (3)
FPG126 mg/dL
twice
Pedersen et al
(IDEAL),16 2005c
7461/8888 (84) Previous MI Atorvastatin 80 mg/
simvastatin 20 mg
or 40 mg
3737/3724 4.8 (4.4-5.0) (1) AE report, (2) DM
medication, (3)
FPG126 mg/dL
twice
Armitage et al
(SEARCH),5 2010
10 797/12 064 (89) Previous MI Simvastatin 80 mg/
simvastatin 20 mg
5398/5399 6.7 (1.4) (1) AE report
Total 32752/39612 (83) 16408/16344 4.9 (1.9)d
Abbreviations: ACS, acute coronary syndrome; AE, adverse event; A to Z, Aggrastat to Zocor trial; DM, diabetes mellitus; CHD, coronary heart disease; FPG, fasting plasma glucose;
IDEAL, Incremental Decrease in End Points Through Aggressive Lipid Lowering study; MI, myocardial infarction; PROVE IT–TIMI 22, Pravastatin or Atorvastatin Evaluation and Infection
Therapy–Thrombolysis in Myocardial Infarction study; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; TNT, Treating to New Targets
study.
SI conversion factor: To convert glucose to mmol/L, multiply by 0.0555.
a“No diabetes” indicates patients who did not have known diabetes mellitus at baseline.
bFollow-up values are mean (SD) for the TNT, SEARCH, and PROVE IT–TIMI 22 studies and median (interquartile range) for the A to Z and IDEAL studies.
cExcluded patients with known diabetes, FPG level of 126 mg/dL or greater, or both at baseline.
dTotal follow-up values are pooled mean (pooled SD).
Table 2. Baseline Data From Trials Comparing Intensive-Dose to Moderate-Dose Statin Therapy
Source
BMI,
Mean
(SD)a
Age,
Mean
(SD), y
HDL,
Mean
(SD),
mg/dL
LDL,
Mean
(SD),
mg/dL
LDL
Reduction,
Relative
%b
ln
Triglycerides,
Mean (SD),
mg/dL
FPG,
Mean
(SD),
mg/dL
FPG
Measured
After
Baseline
Cannon et al (PROVE IT–TIMI 22),18 2004 29 (5) 58 (11) 39 (12) 109 (31) 22 5.05 (0.44) 104 (11)c Not specifiedc
de Lemos et al (A to Z),17 2004 NA 60 (11) 39 (12) 113 (27) 15 5.00 (0.39) NA NA
LaRosa et al (TNT),15 2005d 28 (4) 61 (9) 47 (12) 98 (20) 22 4.89 (0.42) 97 (11) Annually
Pedersen et al (IDEAL),16 2005d 27 (4) 62 (10) 47 (12) 125 (35) 16 4.87 (0.44) 99 (11) Final visit
Armitage et al (SEARCH),5 2010 28 (4) 64 (9) 43 (16)e 98 (23)e 12 4.97 (0.54)e NA NA
Abbreviations: A to Z, Aggrastat to Zocor trial; FPG, fasting plasma glucose; HDL, high-density lipoprotein cholesterol; IDEAL, Incremental Decrease in End Points Through Ag-
gressive Lipid Lowering study; LDL, low-density lipoprotein cholesterol; NA, not available; PROVE IT–TIMI 22, Pravastatin or Atorvastatin Evaluation and Infection Therapy–
Thrombolysis in Myocardial Infarction study; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; TNT, Treating to New Targets study.
SI conversion factors: To convert HDL and LDL cholesterol to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113; glucose to mmol/L, multiply by 0.0555.
aCalculated as weight in kilograms divided by height in meters squared.
bCalculated as [LDL(intensive-dose group)−LDL(moderate-dose group)]/LDL(baseline).
cFor baseline FPG level, there were 315 results from the PROVE IT–TIMI 22 participants, which were similarly distributed between treatment groups.
dExcluded patients with known diabetes, FPG level of 126 mg/dL or greater, or both at baseline.
eNonfasting.
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rates of noncardiovascular death as
compared with moderate-dose statin
therapy (OR, 0.98; 95% CI, 0.87-1.10;
559 cases/16 408 patients receiving in-
tensive therapy vs 571 cases/16 342
patients receiving moderate doses).
There was no significant heteroge-
neity between trials for all-cause mor-
tality (2 for heterogeneity = 7.06;
P=.13; I2=43% [95% CI, 0%-79%]) or
for noncardiovascular death (2 for
heterogeneity = 3.41; P= .49; I2= 0%
[95% CI, 0%-79%]).
Subgroup Analyses
Cardiovascular benefit was consistent
across all subgroups of participants,
including those defined by age,
HDL cholesterol level, triglyceride
concentration, BMI (assessed in 4
trials5,15,16,18; n=29 036; 6192 events), and
FPG level (assessed in 3 trials15,16,18;
n=16 352; 3436 events) above and be-
low the trial medians at baseline
(FIGURE3). The odds of developing dia-
betes among participants receiving in-
tensive compared with moderate statin
therapy was also similar for patients dif-
fering by age, HDL cholesterol level,
BMI (2626 events), and FPG level (1302
events) at baseline but was higher in
those with triglyceride concentrations
below the median compared with those
with higher triglyceride levels. The trial-
specific medians of these variables are
provided in the eTable.
Statin Type and Trial Population
The difference in relative LDL cho-
lesterol reduction between the
more- and less-intensive statin
groups was 12% to 15% in the 2
trials (n=14 301)5,17 that studied sim-
vastatin 80 mg and 16% to 22% in
the 3 trials (n = 18 451)15,16,18 that
studied atorvastatin 80 mg. The odds
of developing diabetes was compa-
rable with simvastatin 80 mg (OR,
1.13; 95% CI, 0.93-1.38; I2=0%; 690
cases/7166 patients receiving simva-
statin 80 mg vs 634 cases/7135
patients with moderate-dose statins)
and atorvastatin 80 mg (OR, 1.15;
95% CI, 1.03-1.28; I2=0%; 759 cases/
9242 patients with atorvastatin 80
mg vs 666 cases/9209 patients with
moderate-dose statin) (P= .56 for
interaction) (eFigure 3). In contrast,
there was no significant cardiovascu-
lar benefit over moderate-dose therapy
in the trials of simvastatin 80 mg (OR,
0.95; 95% CI, 0.88-1.03; I2=0%; 1396
events/7166 patients with simvastatin
Figure 2. Meta-analysis of New-Onset Diabetes and First Major Cardiovascular Events in 5 Large Trials Comparing Intensive-Dose to
Moderate-Dose Statin Therapy
Cases/Total, No. (%)
Intensive
Dose
Moderate
Dose OR (95% CI)Incident Diabetes
101/1707 (5.9) 99/1688 (5.9) 1.01 (0.76-1.34)PROVE IT–TIMI 22,18 2004
65/1768 (3.7) 47/1736 (2.7) 1.37 (0.94-2.01)A to Z,17 2004
418/3798 (11.0) 358/3797 (9.4) 1.19 (1.02-1.38)TNT,15 2005
240/3737 (6.4) 209/3724 (5.6) 1.15 (0.95-1.40)IDEAL,16 2005
625/5398 (11.6) 587/5399 (10.9) 1.07 (0.95-1.21)SEARCH,5 2010
1449/16 408 (8.8) 1300/16 344 (8.0) 1.12 (1.04-1.22)Pooled odds ratio
Heterogeneity:  I2 = 0%; P = .60
Incident CVD
315/1707 (18.4) 355/1688 (21.0) 0.85 (0.72-1.01)PROVE IT–TIMI 22,18 2004
212/1768 (12.0) 234/1736 (13.5) 0.87 (0.72-1.07)A to Z,17 2004
647/3798 (17.0) 830/3797 (21.9) 0.73 (0.65-0.82)TNT,15 2005
776/3737 (20.8) 917/3724 (24.6) 0.80 (0.72-0.89)IDEAL,16 2005
1184/5398 (21.9) 1214/5399 (22.5) 0.97 (0.88-1.06)SEARCH,5 2010
3134/16 408 (19.1) 3550/16 344 (21.7) 0.84 (0.75-0.94)Pooled odds ratio
Heterogeneity:  I2 = 74%; P = .004
0.5 2.01.0
Odds Ratio (95% CI)
0.5 2.01.0
Odds Ratio (95% CI)
Data marker size indicates relative weight of the studies; OR, odds ratio; and CI, confidence interval.
Table 3. Pooled Event Rates and Odds Ratios for Individual Components of the Composite Cardiovascular End Point
End Point
Event Rate (SD) [Events/Patients, No.]a
OR (95% CI) I2 (95% CI), %
Annual
NNTIntensive-Dose Regimen Moderate-Dose Regimen
Cardiovascular death 9.12 (4.78) [759/16 408] 10.04 (5.85) [789/16 342] 0.94 (0.83-1.07) 15 (0-82) 1087
Nonfatal myocardial infarction 13.74 (8.45) [912/16 408] 15.47 (8.54) [1041/16 342] 0.87 (0.79-0.95) 0 (0-79) 578
Nonfatal strokeb 4.74 (1.43) [394/16 407] 5.39 (1.36) [436/16 342] 0.90 (0.78-1.03) 0 (0-79) 1538
Coronary revascularization 27.92 (18.86) [1906/16 407] 33.78 (21.45) [2326/16 343] 0.80 (0.71-0.90) 63 (3-86) 171
Abbreviations: CI, confidence interval; NNT, number needed to treat; OR, odds ratio.
aEvent rate is the number of events per 1000 patient-years.
b Includes fatal and nonfatal strokes from the IDEAL study.16
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80 mg vs 1448 cases/7135 patients with
moderate-dose statin therapy), whereas
there was a significant benefit for ator-
vastatin 80 mg (OR, 0.78; 95% CI, 0.73-
0.85; I2=14%; 1738 events/9242 pa-
tients with atorvastatin 80 mg vs 2102
events/9209 patients with moderate-
dose statin therapy) (P .001 for in-
teraction). Three trials were con-
ducted in patients with stable coronary
heart disease (n=25 853)5,15,16 and 2 in
pat ients fo l lowing recent ACS
(n=6899).17,18 Intensive statin therapy
was associated with higher odds of in-
cident diabetes following ACS (OR,
1.15; 95% CI, 0.85-1.54; 166 cases/
3475 patients with intensive therapy vs
146 cases/3424 patients with moderate-
dose therapy) and in stable coronary
heart disease (OR, 1.12; 95% CI, 1.03-
1.22; 1283 cases/12 933 patients with
intensive therapy vs 1154 cases/
12 920 patients with moderate-dose
therapy), while cardiovascular events
were lower in both conditions (OR,
0.86; 95% CI, 0.76-0.98; 527 events/
3475 patients vs 589 events/3424 pa-
tients; and OR, 0.83; 95% CI, 0.70-
0.98; 2607 events/12 933 patients vs
2961/12 920 patients, respectively)
(eFigure 4); there was no significant
heterogeneity for these outcomes by
study cohort.
Sensitivity Analyses
In sensitivity analyses, the overall
risk of developing diabetes (assessed
in 3 trials5,15,16) and the reduction in
cardiovascular events (assessed in 5
trials), calculated by combining trial-
specific hazard ratios, produced simi-
lar results to the primary analysis (eFig-
ure 5). The risk of developing diabetes
for patients receiving intensive statin
therapy using nonstandard diagnostic
criteria in 2 trials, namely TNT15 and
IDEAL,16 was also qualitatively simi-
lar to the primary analysis in which
standard diagnostic criteria were used
(OR, 1.11; 95% CI, 1.03-1.21) (eFig-
ure 6). Fixed-effects model meta-
analysis produced similar results to ran-
dom-effects model meta-analysis for
new-onset diabetes when pooling data
from the 5 trials.
COMMENT
This study demonstrates that use of
intensive-dose statin therapy com-
pared with moderate-dose statin
therapy was associated with a higher
incidence of new-onset diabetes (OR,
1.12). However, intensive statin
Figure 3. Subgroup Analyses for New-Onset Diabetes and First Major Cardiovascular Events
Incident Diabetes
Incident CVD
Age
BMI
Fasting glucose
HDL cholesterol
Triglycerides
Age
BMI
Fasting glucose
HDL cholesterol
Triglycerides
P Value
.39
.37
.55
.51
.04
.49
.83
.65
.93
.91
Developed Diabetes/No Diabetes
at Baseline, Pooled No.
Intensive
Dose
Moderate
Dose
657/8103 604/8030
792/8305 696/8313
980/7176 865/7102
400/7363 381/7395
574/3874 505/3817
117/4314 106/4347
504/7698 430/7648
943/8516 863/8491
944/8049 892/7914
503/8165 402/8228
1688/8103 1853/8030
1446/8305 1697/8313
1399/7176 1599/7102
1504/7363 1690/7395
753/3874 918/3817
796/4314 969/4347
1392/7698 1561/7648
1709/8516 1953/8491
1572/8049 1763/7914
1529/8165 1751/8228
OR (95% CI)
1.09 (0.97-1.22)
1.16 (1.04-1.30)
1.15 (1.03-1.28)
1.06 (0.92-1.22)
1.15 (1.01-1.31)
1.02 (0.65-1.61)
1.17 (1.03-1.34)
1.11 (1.01-1.23)
1.06 (0.96-1.17)
1.27 (1.11-1.45)
0.87 (0.77-0.98)
0.82 (0.73-0.92)
0.83 (0.73-0.95)
0.85 (0.73-0.99)
0.76 (0.68-0.85)
0.79 (0.70-0.89)
0.85 (0.73-0.98)
0.84 (0.76-0.93)
0.84 (0.73-0.96)
0.85 (0.77-0.93)
Above median
Below median
Above median
Below median
Above median
Below median
Above median
Below median
Above median
Below median
Above median
Below median
Above median
Below median
Above median
Below median
Above median
Below median
Above median
Below median
0.5 2.01.0
Odds Ratio (95% CI)
0.5 2.01.0
Odds Ratio (95% CI)
Data were available for age, high-density lipoprotein (HDL) cholesterol levels, and triglyceride concentrations in all trials; for body mass index (BMI) in 4 trials; and for
fasting plasma glucose levels in 3 trials. The medians of the variables are per-trial medians, which are provided in the eTable. P values apply to heterogeneity between
groups. Data marker size indicates relative weight of the studies; OR, odds ratio; and CI, confidence interval.
INTENSIVE-DOSE VS MODERATE-DOSE STATIN THERAPY
©2011 American Medical Association. All rights reserved. JAMA, June 22/29, 2011—Vol 305, No. 24 2561
Downloaded From: http://jama.jamanetwork.com/ by a Imperial College London User  on 08/23/2016
therapy was associated with fewer
major cardiovascular events (OR,
0.84). In this combined trial popula-
tion, although the risk of new-onset
diabetes and the benefit of cardiovas-
cular event reduction for patients
receiving intensive therapy were
similar in relative terms, when
expressed in absolute terms there
was 1 additional case of diabetes for
every 498 patients treated for 1 year
compared with 1 fewer patient expe-
riencing a cardiovascular event for
every 155 patients treated for 1 year.
The cardiovascular benefit described
here may be a conservative estimate
because 3 trials have demonstrated
that intensive statin therapy also
reduces multiple cardiovascular
events if intensive statin therapy is
cont inued. 2 2 - 2 4 These f indings
complement the recent observation
of excess risk of developing diabetes
among patients treated with statins
compared with those receiving pla-
cebo.4
The benefits of statin therapy were
consistent across all subgroups and
for each component of the primary
efficacy end point, including cardio-
vascular death. Analyses of all-cause
mortality were consistent with obser-
vations for cardiovascular death,
although the generalizability of these
findings to other populations is less
clear because these depend on the
relative contributions of cardiovascu-
lar death (modified by statins) and
noncardiovascular death (nonmodifi-
able by statins) in those populations.
For new-onset diabetes, however,
there was some evidence that the
odds of new-onset diabetes was
higher among individuals with tri-
glyceride concentrations below the
median level of distribution with
intensive statin treatment, which, in
the absence of a biologically plau-
sible mechanism, may be a chance
finding given the modest statistical
significance in the context of mul-
tiple statistical tests. The higher inci-
dence of new-onset diabetes and
lower incidence of cardiovascular
events were similar in patients fol-
lowing recent ACS and those with
stable coronary disease. In the trials
we studied whose control groups
were different but comparable, the
relative LDL-cholesterol reduction
was greater in those that used atorva-
statin 80 mg than in those that used
simvastatin 80 mg.25 Whereas the
odds of developing diabetes was
similar on both, there was a signifi-
cantly lower odds of cardiovascular
events in the trials with high-dose
atorvastatin but not with high-dose
simvastatin.1
Important questions remain. First,
a potential mechanism to explain the
findings of a higher incidence of dia-
betes with statin therapy compared
with placebo, and intensive-dose
therapy compared with moderate-
dose therapy, has not been identified.
Possibilities include a direct and off-
target effect. For example, statins
may influence muscle or liver insulin
action directly, resulting in higher
diabetes risk. Data from an animal
model suggest that statin-induced
myopathy is associated with the
development of muscle insulin resis-
tance, providing a potential mecha-
nism.26 Second, it remains unclear
whether statin therapy is associated
with a generalized tendency for an
increase in diabetes risk in many
who take statins or whether there is a
specific group of individuals at par-
ticular risk. Analysis of data from
subgroups did not provide conclu-
sive data. Third, although statin
therapy is associated with a higher
incidence of diabetes, to what extent
this may carry with it the important
associated long-term risks of devel-
oping microvascular disease is
unknown. To date, no large clinical
studies have examined the associa-
tions of statin therapy with microvas-
cular disease. In contrast, fibrate
therapy is associated with lower rates
of microvascular complications.27,28
We hypothesize that given that car-
diovascular risk from diabetes is
modest in the first decade after diag-
nosis,29 and as the benefit of statin
therapy increases over time and in
absolute terms with increasing age,30
net cardiovascular benefit in high-
risk individuals will still strongly
favor statin therapy. Finally, it would
be of interest to investigate the
impact of intensive statin therapy on
glycemic control and treatment
requirements in patients with estab-
lished diabetes. One consideration to
help quantify potential concerns is
the establishment of a registry to
examine these issues of long-term
risk. Our findings suggest that clini-
cians should be vigilant for the devel-
opment of diabetes in patients receiv-
ing intensive statin therapy.
Strengths of this meta-analysis
include the following: first, we were
able to include data from all the rel-
evant clinical trials and thereby pro-
vide adequate power to detect poten-
tially modest effects. Second, access
to trial data allowed relevant sub-
group analyses. And third, it was
possible to provide a comparison of
the potential risk of new-onset diabe-
tes with cardiovascular benefit,
thereby providing clinically useful
information. Potential weaknesses
include the following: first, different
methods for diagnosing diabetes
were available for the 5 trials, and the
trials were not designed to assess
new-onset diabetes. However, the
low heterogeneity in new-onset dia-
betes as well as the very similar sen-
sitivity analysis using the nonstan-
dard criteria in 2 trials provides
confidence in the results obtained.
Second, analyses of incident diabetes
were not prespecified in the trial
designs and only 1 trial (TNT15)
included regular measurement of
FPG as a consequence. Because undi-
agnosed diabetes is relatively com-
mon,31 it is possible that we may
have somewhat underestimated the
risk of incident diabetes in the trial
participants. Third, because all 5
trials specifically included partici-
pants with established coronary dis-
ease at high risk of future cardiovas-
cular events rather than diabetes, our
findings may not necessarily be gen-
eralizable to populations at higher
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risk of incident diabetes. Fourth,
analyses were conducted without
access to individual participant data.
Fifth, we cannot exclude the possi-
bility that intensive statin therapy
may have caused more adverse
effects and therefore led to differ-
ences in routine clinical care between
those treated with intensive- and
moderate-dose regimens, resulting in
detection bias.
In conclusion, this meta-analysis ex-
tends earlier findings of an increased in-
cidence of diabetes with statin therapy
by providing evidence of a dose-
dependent association.
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We feel safe, huddled within human institutions—
churches, banks, madrigal groups—but these con-
nections melt away at the basic moment. The self’s re-
sponsibility, then, is to achieve rapport if not rapture
with the giant, cosmic other: to appreciate, let’s say,
the walk back from the mailbox.
—John Updike (1932-2009)
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